1106 related articles for article (PubMed ID: 25421010)
41. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
Tian F; Shen Y; Chen Z; Li R; Lu J; Ge Q
Gene; 2016 Oct; 591(2):338-43. PubMed ID: 27291819
[TBL] [Abstract][Full Text] [Related]
42. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
Su K; Zhang T; Wang Y; Hao G
World J Surg Oncol; 2016 Aug; 14(1):224. PubMed ID: 27733164
[TBL] [Abstract][Full Text] [Related]
44. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer.
Tang D; Shen Y; Wang M; Yang R; Wang Z; Sui A; Jiao W; Wang Y
Eur J Cancer Prev; 2013 Nov; 22(6):540-8. PubMed ID: 23462458
[TBL] [Abstract][Full Text] [Related]
45. Circulating microRNAs as biomarkers of adult Crohn's disease.
Jensen MD; Andersen RF; Christensen H; Nathan T; Kjeldsen J; Madsen JS
Eur J Gastroenterol Hepatol; 2015 Sep; 27(9):1038-44. PubMed ID: 26230660
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of serum miR-25 in non-small-cell lung cancer.
Li J; Yu M; Liu Z; Liu B
Br J Biomed Sci; 2019 Jul; 76(3):111-116. PubMed ID: 30919763
[No Abstract] [Full Text] [Related]
47. Evaluating the diagnostic and prognostic value of serum miR-770 in non-small cell lung cancer.
Sun B; Liu HF; Ding Y; Li Z
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3061-3066. PubMed ID: 29863251
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of Serum Paired MicroRNA Ratios for Differential Diagnosis of Non-Small Cell Lung Cancer and Benign Pulmonary Diseases.
Fan L; Sha J; Teng J; Li D; Wang C; Xia Q; Chen H; Su B; Qi H
Mol Diagn Ther; 2018 Aug; 22(4):493-502. PubMed ID: 29922886
[TBL] [Abstract][Full Text] [Related]
49. Combination of serum miRNAs with Cyfra21-1 for the diagnosis of non-small cell lung cancer.
Zhou C; Chen Z; Dong J; Li J; Shi X; Sun N; Luo M; Zhou F; Tan F; He J
Cancer Lett; 2015 Oct; 367(2):138-46. PubMed ID: 26213369
[TBL] [Abstract][Full Text] [Related]
50. Circulating Plasma miRNAs as Potential Biomarkers of Non-Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling.
Niu Y; Su M; Wu Y; Fu L; Kang K; Li Q; Li L; Hui G; Li F; Gou D
Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):327-336. PubMed ID: 30377207
[TBL] [Abstract][Full Text] [Related]
51. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer.
Zhang H; Mao F; Shen T; Luo Q; Ding Z; Qian L; Huang J
Oncol Lett; 2017 Feb; 13(2):669-676. PubMed ID: 28356944
[TBL] [Abstract][Full Text] [Related]
52. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
53. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
54. Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC.
Ulivi P; Foschi G; Mengozzi M; Scarpi E; Silvestrini R; Amadori D; Zoli W
Int J Mol Sci; 2013 May; 14(5):10332-42. PubMed ID: 23681013
[TBL] [Abstract][Full Text] [Related]
55. Plasma miR-92a-2 as a biomarker for small cell lung cancer.
Yu Y; Zuo J; Tan Q; Zar Thin K; Li P; Zhu M; Yu M; Fu Z; Liang C; Tu J
Cancer Biomark; 2017; 18(3):319-327. PubMed ID: 28106539
[TBL] [Abstract][Full Text] [Related]
56. Circulating miRNA-21 and miRNA-23a Expression Signature as Potential Biomarkers for Early Detection of Non-Small-Cell Lung Cancer.
Hetta HF; Zahran AM; Shafik EA; El-Mahdy RI; Mohamed NA; Nabil EE; Esmaeel HM; Alkady OA; Elkady A; Mohareb DA; Hosni A; Mostafa MM; Elkady A
Microrna; 2019; 8(3):206-215. PubMed ID: 30652656
[TBL] [Abstract][Full Text] [Related]
57. Differential expression levels of plasma microRNA in Hashimoto's disease.
Zhao L; Zhou X; Shan X; Qi LW; Wang T; Zhu J; Zhu D; Huang Z; Zhang L; Zhang H; Yin Y; Wang Z; Zhu W; Cheng W; Jiang L
Gene; 2018 Feb; 642():152-158. PubMed ID: 29054761
[TBL] [Abstract][Full Text] [Related]
58. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
[TBL] [Abstract][Full Text] [Related]
59. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
[TBL] [Abstract][Full Text] [Related]
60. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
